Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Naglazyme Sales and Development Funds Grow for AnGes MG in April-December
February 12, 2013
- Eli Lilly to Discontinue Development of Tabalumab for RA
February 12, 2013
- Will Lotriga Create a New Market or Battle Head to Head with Epadel?
February 12, 2013
- Ethical Drug Sales Down 2.5% in December: Crecon Report
February 8, 2013
- Seikagaku to Initiate PII Trial in Japan of Knee Osteoarthritis Treatment
February 8, 2013
- Chugai Applies for Once-Weekly Herceptin for Postoperative Adjuvant Chemotherapy in Breast Cancer Based on Data from Public Domain
February 8, 2013
- Asahi Kasei Pharma Reports Strong Growth for April-December 2012; Sales of Teribone Break 12 Billion Yen Mark
February 8, 2013
- Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
- DSP President Expects Launch of PMDA-WEST, Says Kansai Firms Are at Disadvantage
February 7, 2013
- EMA Approves Otsuka’s Abilify for the Treatment of Manic Episodes in Bipolar I Disorder in Adolescents
February 7, 2013
- 4 Major Wholesalers’ Price Settlement Rates Lower than 2 Years Ago, Negotiations Charging into Final Phase: April-Dec. Earnings
February 7, 2013
- Novartis Jettisons Key Evidence from Diovan Promotion
February 6, 2013
- Sales and Profits Jump for Shionogi in April-December with US Sales Recovery
February 6, 2013
- Latuda Serves as Driving Force for Growth in North American Market: DSP President Tada
February 6, 2013
- Takeda Lowers Full-Year Sales Forecast for Nesina, but Says Nesina Remains “Fastest-Growing DPP-4 Inhibitor”
February 6, 2013
- Sales in Emerging Markets Contribute to Growth in Sales for April-December Despite Fall in Sales of All 4 Major Products: Takeda
February 6, 2013
- Daiichi Sankyo Starts PIII Trial of ARQ 197 in HCC Patients
February 5, 2013
- DSP Posts 46.5 % Rise in April-December Operating Profit Despite Japan Sales Fall
February 5, 2013
- Nesp, Mircera Jostling for Market Shares of Pre-Dialysis CKD Patients
February 5, 2013
- Teijin Pharma Appoints Hiroshi Uno as New President Effective from April 1
February 5, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…